FallberichtOpen Access
Linear IgA Bullous Dermatosis: A Rare Immune-Related Cutaneous Adverse Event Due to Pembrolizumab
Cureus · 23.07.2026
DOI: 10.7759/cureus.113216 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cureus, erschienen am 23.07.2026. Verfasst von Lakshya Motwani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, Mercy Health - St. Vincent Medical Center, Toledo, USA. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
immune checkpointimmune checkpoint inhibitor adverse effectsimmune-related adverse event (irae)linear iga bullous dermatosispembrolizumabpembrolizumab cutaneous side effect
Autor:innen und Institutionen
- Internal Medicine, Mercy Health - St. Vincent Medical Center, Toledo, USA.
- Dermatology, Mercy Health - St. Vincent Medical Center, Toledo, USA.
Zitieren
APA
Motwani, L., Doddapaneni, V. K., & Heuring, E. L. (2026). Linear IgA Bullous Dermatosis: A Rare Immune-Related Cutaneous Adverse Event Due to Pembrolizumab. Cureus. https://doi.org/10.7759/cureus.113216
Vancouver
Motwani L, Doddapaneni VK, Heuring EL. Linear IgA Bullous Dermatosis: A Rare Immune-Related Cutaneous Adverse Event Due to Pembrolizumab. Cureus. 2026. doi:10.7759/cureus.113216
BibTeX
@article{Motwani2026,
author = {Motwani, Lakshya and Doddapaneni, Vijay Kumar and Heuring, Erin L},
title = {Linear IgA Bullous Dermatosis: A Rare Immune-Related Cutaneous Adverse Event Due to Pembrolizumab},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.113216}
}
EUVIMED